NANJING, China, June 1, 2023--Nanjing Leads Biolabs Co.,Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the latest updated clinical data on the safety and efficacy of its anti-LAG-3 (lymphocyte activating gene-3) antibody LBL-007 and toripalimab combination therap
NANJING, China, April 27, 2023--Nanjing Leads Biolabs Co.,Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the first participant has been successfully dosed in a Phase Ⅰ/Ⅱ, first in human, multicenter, open-labeled, dose escalation and expansion study of LBL-033, a
Leads Biolabs © Nanjing Leads Biolabs Co.,Ltd. | 苏ICP备18069235号-1